10-13C
Some sunny spells are expected in the far south.

Find a...

Date Job Car Home















Global biotech firm to create over 100 jobs at Cork plant

A global biotech giant is to create more than 100 jobs at its manufacturing facility in Cork.

BioMarin Pharmaceuticals made the announcement yesterday as it marked its first anniversary in Ireland.

The company, which specialises in the manufacture of drugs used in the treatment of extremely rare genetic diseases, acquired the manufacturing plant in Shanbally from Pfizer last year for close to $48.5m (€38.6m).

BioMarin said that most of the planned manufacturing activities at the plant were tied to the results of a clinical study for a drug known as N-acetylgalactosamine 6-sulfatase, or GALNS — an experimental therapy used in the treatment of mucopolysaccharidosis, also known as Morquio A syndrome.

This is caused by the failure to break down certain material in tissues and organs and results in difficulty walking, breathing, and bone and joint problems.

It is expected that the Cork plant will be licensed for GALNS production by 2015. The company will begin recruitment towards the end of the year.

Robert Baffi, BioMarin’s executive vice president of technical operations, said: “We are delighted to announce that we expect our expansion into Ireland will create 100 plus jobs in the 2013-2015 timeframe.

“A handful of positions will open later this year and to fill these and other positions, we are preparing for a biotech career day on Sept 12 here at the facility.

“This is an exciting development for us and big news for the region at large.”

Dan Maher, the senior vice-president of product development at BioMarin, said: “We have a robust pipeline of potential treatments ready for eventual manufacturing here in Shanbally.”

The announcement was made as the company hosted a rare disease information day at the plant.

Senior company executives highlighted the progress the company has made in developing therapeutic options to treat some of the world’s rarest genetic diseases.

It has expanded its manufacturing facility in Novato, California, to support $1bn in revenue.

It acquired the Cork plant in part to help it meet extra manufacturing capabilities it expects to support growing sales for drugs like GALNS.

Its approved products include galsulfase for one form of mucopolysaccharidosis, laronidase for another form of the disease and sapropterin dihydrochloride tablets for phenylketonuria (PKU).

The latter describes the inability properly break down an amino acid called phenylalanine Home

More from the Irish Examiner